Volatilome is Inflammasome- and Lipidome-dependent in Ischemic Heart Disease
- PMID: 39039680
- PMCID: PMC11440324
- DOI: 10.2174/011573403X302934240715113647
Volatilome is Inflammasome- and Lipidome-dependent in Ischemic Heart Disease
Abstract
Ischemic heart disease (IHD) is a pathology of global interest because it is widespread and has high morbidity and mortality. IHD pathophysiology involves local and systemic changes, including lipidomic, proteomic, and inflammasome changes in serum plasma. The modulation in these metabolites is viable in the pre-IHD, during the IHD period, and after management of IHD in all forms, including lifestyle changes and pharmacological and surgical interventions. Therefore, these biochemical markers (metabolite changes; lipidome, inflammasome, proteome) can be used for early prevention, treatment strategy, assessment of the patient's response to the treatment, diagnosis, and determination of prognosis. Lipidomic changes are associated with the severity of inflammation and disorder in the lipidome component, and correlation is related to disturbance of inflammasome components. Main inflammasome biomarkers that are associated with coronary artery disease progression include IL-1β, Nucleotide-binding oligomerization domain- like receptor family pyrin domain containing 3 (NLRP3), and caspase-1. Meanwhile, the main lipidome biomarkers related to coronary artery disease development involve plasmalogen lipids, lysophosphatidylethanolamine (LPE), and phosphatidylethanolamine (PE). The hypothesis of this paper is that the changes in the volatile organic compounds associated with inflammasome and lipidome changes in patients with coronary artery disease are various and depend on the severity and risk factor for death from cardiovascular disease in the time span of 10 years. In this paper, we explore the potential origin and pathway in which the lipidome and or inflammasome molecules could be excreted in the exhaled air in the form of volatile organic compounds (VOCs).
Keywords: Lipidome; VOCs; coronary artery disease.; inflammasome; ischemic heart disease; metabolome.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Conflict of interest statement
The authors declare no conflict of interest, financial or otherwise.
Figures


Similar articles
-
Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.Mol Neurobiol. 2016 Jul;53(5):3462-3476. doi: 10.1007/s12035-015-9242-y. Epub 2015 Jun 20. Mol Neurobiol. 2016. PMID: 26091790
-
Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction.J Cardiovasc Transl Res. 2021 Feb;14(1):23-34. doi: 10.1007/s12265-020-10049-w. Epub 2020 Jul 9. J Cardiovasc Transl Res. 2021. PMID: 32648087 Free PMC article. Review.
-
Integrative analyses of myocardial lipidome and proteome implicate mitochondrial dysfunction in lethal ventricular tachyarrhythmia (LVTA) induced by acute myocardial ischemia (AMI).J Proteomics. 2019 Apr 15;197:14-22. doi: 10.1016/j.jprot.2019.01.021. Epub 2019 Feb 4. J Proteomics. 2019. PMID: 30731211
-
Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases.Front Immunol. 2019 Jul 10;10:1592. doi: 10.3389/fimmu.2019.01592. eCollection 2019. Front Immunol. 2019. PMID: 31354731 Free PMC article. Review.
-
Sodium tanshinone IIA sulfonate ameliorates ischemia-induced myocardial inflammation and lipid accumulation in Beagle dogs through NLRP3 inflammasome.Int J Cardiol. 2015 Oct 1;196:183-92. doi: 10.1016/j.ijcard.2015.05.152. Epub 2015 May 29. Int J Cardiol. 2015. PMID: 26143630
Cited by
-
Volatilome and machine learning in ischemic heart disease: Current challenges and future perspectives.World J Cardiol. 2025 Apr 26;17(4):106593. doi: 10.4330/wjc.v17.i4.106593. World J Cardiol. 2025. PMID: 40308617 Free PMC article.
-
Development and validation of a machine learning model for diagnosis of ischemic heart disease using single-lead electrocardiogram parameters.World J Cardiol. 2025 Apr 26;17(4):104396. doi: 10.4330/wjc.v17.i4.104396. World J Cardiol. 2025. PMID: 40308623 Free PMC article. Clinical Trial.
-
Machine Learning Model Discriminate Ischemic Heart Disease Using Breathome Analysis.Biomedicines. 2024 Dec 11;12(12):2814. doi: 10.3390/biomedicines12122814. Biomedicines. 2024. PMID: 39767720 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical